NEW YORK, December 30, 2025, 19:42 ET — After-hours
- Merck shares closed down 0.53% at $106.06 and edged higher in after-hours trading.
- The stock remains near its 52-week high after a quiet, holiday-thin session on Wall Street.
- Investors are watching for Merck’s Feb. 3 earnings call and the company’s early-January dividend.
Merck & Company, Inc. (MRK) shares fell 0.53% to $106.06 at the close on Tuesday and were up about 0.1% in after-hours trading at $106.17. The stock has traded between $73.31 and $107.59 over the past 52 weeks.
The muted move matters now because liquidity typically thins into year-end, which can exaggerate small price swings even in defensive healthcare names. Merck has scheduled its fourth-quarter earnings call for Feb. 3, putting its 2026 outlook in focus as investors reset positions for the new year.
Wall Street’s main indexes closed slightly lower in choppy holiday trading, and investors parsed the Federal Reserve’s meeting minutes — the written record of policymakers’ debate about the economy and interest rates. “The growth rates are going to converge between technology and everything else next year,” said Mark Hackett, chief market strategist at Nationwide, describing the recent shift as a rotation rather than a panic move. Reuters
Merck traded between $105.64 and $106.84 in the regular session, with about 6.5 million shares changing hands. The stock opened at $106.73, leaving Tuesday’s low as the nearest “support” level — a price area where buyers have recently stepped in.
Big pharma peers were also subdued. Johnson & Johnson fell 0.31% and Pfizer slipped 0.04% in the same session, keeping sector moves modest as investors wound down positions into the final stretch of the year.
Merck is one of the biggest U.S. drugmakers, best known for cancer immunotherapy Keytruda, vaccines and an animal health business. The company’s growth mix remains a core investor debate as the market weighs how quickly Merck can add new products alongside its biggest franchise.
Income investors also have a near-term date on the calendar. Merck said its board declared a quarterly dividend of $0.85 per share, payable Jan. 8 to shareholders of record as of Dec. 15.
Dividend-paying drugmakers often draw steady interest when investors turn cautious, but year-end flows can still dominate day-to-day price action. In thin sessions, a small program trade can move a stock more than it would in normal volume.
For Merck, the next clear company catalyst is the Feb. 3 earnings report and call, when investors will look for guidance on 2026 sales trends and the pace of spending on late-stage research. Any change in the company’s tone on its largest products tends to outweigh incremental daily market moves.
In technical terms, “resistance” is the area where rallies have tended to fade, while “support” is where dips have found buyers. For MRK, Tuesday’s low is the closest support marker, while the recent peak remains the next upside test.
Outside the company, traders are also watching macro signals after the Fed minutes and heading into early-January data. With holiday volumes still light, abrupt moves can show up quickly in single-stock trading before fundamentals take over again.
